AJP - Renal Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Renal Physiol 288: F658-F664, 2005. First published November 30, 2004; doi:10.1152/ajprenal.00392.2004
0363-6127/05 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
288/4/F658    most recent
00392.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Che, Q.
Right arrow Articles by Carmines, P. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Che, Q.
Right arrow Articles by Carmines, P. K.

Src family kinase involvement in rat preglomerular microvascular contractile and [Ca2+]i responses to ANG II

Qi Che and Pamela K. Carmines

Department of Cellular and Integrative Physiology, University of Nebraska College of Medicine, Omaha, Nebraska

Submitted 26 October 2004 ; accepted in final form 26 November 2004


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Experiments were performed to investigate the potential role of Src family kinase(s) in the rat afferent arteriolar contractile response to ANG II. The in vitro blood-perfused juxtamedullary nephron technique was employed to monitor afferent arteriolar lumen diameter responses to 1–100 nM ANG II before and during Src family kinase inhibition (10 µM PP2). PP2 did not alter baseline diameter but attenuated ANG II-induced contractile responses by 33 ± 6%. An inactive analog of PP2 (PP3) had no effect on ANG II-induced afferent arteriolar contraction. The effect of Src kinase inhibition on ANG II-induced intracellular free Ca2+ concentration ([Ca2+]i) responses was probed in fura 2-loaded preglomerular microvascular smooth muscle cells (PVSMCs) obtained from explants and studied after 3–5 days in culture. In untreated PVSMCs, ANG II evoked peak ({Delta} = 293 ± 66 nM) and plateau ({Delta} = 23 ± 8 nM) increases in [Ca2+]i. In PVSMCs pretreated with PP2, baseline [Ca2+]i was unaltered, but both the peak ({Delta} = 140 ± 22 nM) and plateau ({Delta} = 3 ± 2 nM) phases of the ANG II response were significantly reduced compared with untreated cells. PP3 did not alter [Ca2+]i responses to ANG II. Immunoprecipitation and Western blot analysis confirmed that 100 nM ANG II increased phosphorylation of c-Src (at Y416) in PVSMCs. The phosphorylation response was maximal 1 min after ANG II exposure and was prevented by PP2. We conclude that the preglomerular vasoconstriction evoked by ANG II involves rapid c-Src activation with subsequent effects that contribute to the [Ca2+]i response to the peptide.

tyrosine kinase; vascular smooth muscle; afferent arteriole

ANG II ELICITS DIVERSE CELLULAR responses in the vasculature, including contraction, proliferation, migration, and inflammation (42). The vasoconstrictor response to ANG II requires engagement of the AT1 receptor (AT1R) (39), which activates a signaling network that ultimately leads to an increase in intracellular free Ca2+ concentration ([Ca2+]i) and contraction. Protein tyrosine kinases modulate ANG II-stimulated [Ca2+]i, intracellular pH, contraction, and growth responses of vascular smooth muscle cells (VSMCs), and tyrosine kinase inhibitors attenuate ANG II-induced effects in large arteries or cultured aortic myocytes (41). In accord with such observations, our previous studies revealed that renal afferent arteriolar contractile responses to ANG II involve tyrosine kinase(s), including the epidermal growth factor receptor (EGFR) tyrosine kinase (5, 10). Although the mechanism linking the AT1R and the EGFR has not been established, it may involve activation of intervening tyrosine kinase(s) (4, 12, 13, 48). The candidate tyrosine kinases include Src kinases (13, 19, 24, 50), a family of widely expressed nonreceptor tyrosine kinases. There exist at least 14 Src-related kinases, of which the 60-kDa c-Src is the prototype (38). c-Src is highly expressed in VSMCs (30) and has been implicated as a candidate tyrosine kinase that mediates regulation of vascular smooth muscle tone. Src family kinases have been implicated in stretch-induced contraction of the bovine coronary artery (31), the canine basilar artery contractile responses to low extracellular Mg2+ concentration (47) and endothelin-1 (49), {alpha}2-adrenergic contraction of the porcine palmar lateral vein (34) (but not the rat thoracic aorta) (8), the contraction of the rat aorta evoked by 5-hydroxytryptamine (3), and ANG II-induced contraction in the mesenteric vasculature (43). However, no data are available concerning the potential role of Src in regulating renal microvascular function. The present study was performed to evaluate the hypothesis that Src family kinase activation contributes to afferent arteriolar contractile and [Ca2+]i responses to ANG II.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Animals. The procedures used in this study were approved by the University of Nebraska Medical Center Institutional Animal Care and Use Committee and conducted according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Male Sprague-Dawley rats (SAS:VAF strain) weighing 250–300 g were purchased from Charles River Laboratories (Wilmington, MA) and provided free access to food and water.

In vitro blood-perfused juxtamedullary nephron technique. Arteriolar contractile function was assessed using the rat in vitro blood-perfused juxtamedullary nephron technique (9). After anesthetization with pentobarbital sodium (50 mg/kg ip), a cannula was inserted into the left carotid artery and enalaprilat was administered (2 mg in 1 ml isotonic saline) to reduce endogenous ANG II formation. The left renal artery and vein were ligated, and the right renal artery was cannulated through the superior mesenteric artery, thereby initiating renal perfusion with Tyrode’s solution containing 52 g/l dialyzed BSA and a mixture of L-amino acids (32). Blood was collected through the carotid cannula before the kidney was harvested. Renal perfusion was maintained throughout the ensuing dissection procedure needed to reveal the tubules, glomeruli, and related vasculature of the juxtamedullary nephrons. Tight ligatures were placed around the most distal accessible segments of the large arterial branches that supply the exposed microvasculature. Acute surgical papillectomy was performed to avoid the indirect, tubuloglomerular feedback-dependent influence of ANG II on the afferent arteriole (22). The Tyrode’s perfusate was then replaced with reconstituted blood, prepared as described previously (32). Renal arterial perfusion pressure was maintained at 110 mmHg throughout the experiment. The perfusion chamber was warmed, and the tissue surface was bathed continuously with Tyrode’s solution containing 10 g/l BSA at 37°C. The tissue was transilluminated on the fixed stage of a compound microscope equipped with a water-immersion objective (x40). A single afferent arteriole was selected for study based on visibility and acceptable blood flow (the inability to discern the passage of individual erythrocytes), and the ensuing protocol assessed arteriolar diameter at a single measurement site (>100 µm upstream of the glomerulus) under several experimental conditions. Video images of the microvessels were stored on a DVD for later analysis, during which lumen diameter was measured at 12-s intervals with a digital image-shearing monitor. This device was calibrated using a stage micrometer (smallest division = 2 µm) and yielded diameter measurements reproducible to within <1 µm. The average diameter during the final minute of each treatment period was utilized for statistical analysis.

Culture of preglomerular microvascular smooth muscle cells. Preglomerular microvascular smooth muscle cells (PVSMCs) were cultured from the rat kidney by the explant method. Briefly, animals were anesthetized with pentobarbital sodium (50 mg/kg ip) and the abdominal aorta was cannulated to allow renal perfusion with physiological saline solution (PSS), followed by 400 U/ml collagenase in GIBCO 0.05% trypsin-EDTA for 5 min, then 1% Fe3O4 in PSS. The kidneys were removed and the cortex was minced, transferred to 1,100 U/ml collagenase and 400 U/ml hyaluronidase in PSS, and incubated at 37°C with gentle shaking for 30 min. Iron oxide-laden tissue was isolated from the suspension using a magnet, washed four to five times with cold PSS, and incubated in 270 U/ml collagenase at 37°C with gentle shaking for 10 min. The iron-containing tissue was again collected, washed with cold PSS, and inspected under the microscope to confirm that it consisted of microvessels devoid of glomeruli. The microvessels were transferred to DMEM containing 20% FCS, 100 U/ml penicillin, and 100 µg/ml streptomycin (14). Cultures were maintained in 5% CO2 (balance air) at 37°C and 85% humidity. All studies using cultured PVSMCs were performed after growth arrest under serum-free conditions for 1 day.

Immunostaining of PVSMCs. Cells obtained from the preglomerular microvasculature by the explant method and seeded onto glass coverslips were washed with cold PBS and fixed with 1:1 methanol:acetone at –20°C for 20 min. The coverslips were washed with cold PBS, blocked by 10% goat serum in PBS, and incubated overnight at 4°C with either mouse monoclonal anti-myosin heavy chain (1:100) or mouse monoclonal anti-CD34 (1:100). After four washes with cold PBS, the coverslips were incubated in the dark at room temperature for 30 min with Texas red-conjugated goat anti-mouse antibody (1:200). Unbound antibodies were removed by four washes with 3% BSA in PBS. The coverslips were incubated at room temperature in 2 µg/ml bisbenzimide H 33258 (nuclear dye) and FITC-conjugated mouse monoclonal anti-{alpha}-smooth muscle actin (1:500). After a final wash (3% BSA in PBS, repeated 3 times), the cells were dehydrated in ethanol, fixed with mounting media to glass slides, viewed under epifluorescence using a Leica DMR research microscope, and photographed with an Optronics Magnafire digital camera.

[Ca2+]i measurement. PVSMCs were allowed to migrate from the primary explants onto glass coverslips and studied after 3–5 days in culture (with the final day under serum-free conditions). [Ca2+]i was monitored in fura 2-loaded cells using dual-excitation wavelength fluorescence microscopy, as described previously (6, 17). Briefly, cells were loaded with fura 2 by 1-h exposure at room temperature to Ringer solution containing 7 µM fura 2-AM, 0.09 g/dl DMSO, and 0.018 g/dl Pluronic F-127. An adjustable optical sampling window was positioned over a single PVSMC, which was illuminated alternately at 340- and 380-nm excitation wavelengths while emission fluorescence (510 nm) was collected using a photometer assembly at a rate of 10 points/s. [Ca2+]i was calculated from background-corrected data with the use of the FeliX software package (version 1.42; Photon Technology International, Monmouth Junction, NJ) according to the standard equation with a 0.85 viscosity correction factor (16, 33). Calibration of the fura 2 signal was performed daily using established methods previously described (6, 16). The protocol was as follows: after a stabilization period, baseline afferent arteriolar [Ca2+]i was determined during exposure to a normal Ringer bath. The vessel was then subjected to one of the following 10-min treatments: 1) untreated (no drugs); 2) exposure to 10 µM 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]-pyrimidine (PP2; Src family kinase inhibitor); or 3) exposure to 10 µM 4-amino-7-phenylpyrazolo[3,4-d]pyrimidine (PP3; the inactive analog of PP2). Finally, 100 nM ANG II was applied in the continued presence of the pretreatment drug. None of these compounds exhibited autofluorescence at the excitation and emission wavelengths used for fura 2.

Immunoprecipitation and immunoblotting. PVSMCs were grown to confluence in flasks, passaged three to five times, and harvested using GIBCO 0.05% trypsin-EDTA. Quiescent PVSMCs were pretreated with or without 10 µM PP2 for 30 min, followed by exposure to 100 nM ANG II for different durations (0, 0.5, 1, 2, and 5 min). Cells were washed with ice-cold PBS, and excess solution was tapped off. Cells were lysed in 0.5 ml lysis buffer (in mM: 50 Na4P2O7, 50 NaF, 50 NaCl, 5 EDTA, 5 EGTA, 2 Na3VO4, and 10 HEPES as well as 0.1% Triton X-100) and 0.1 ml protease inhibitor cocktail for mammalian tissue (Sigma). The samples were quickly put on dry ice for 15 min, thawed on ice for 15 min, sonicated, and spun at 12,000 g for 20 min at 4°C. The supernatants were quantitated using a detergent-compatible protein assay (Bio-Rad, Hercules, CA). Normalized protein lysates were immunoprecipitated with mouse monoclonal anti-c-Src at 4°C for 1 h, and then protein G-Sepharose was added and incubated overnight at 4°C. Immune complexes were washed three times in PBS containing 1% Nonidet P-40, 0.5% Na deoxycholate, and 0.1% SDS and resuspended in SDS sample buffer (1.25% {beta}-mercaptoethanol, 0.75% SDS, 3.125% 4x upper Tris, 2.5 mg/100 ml pyronin Y, 10 mg/100 ml bromophenol blue, 6.25% glycerol). Proteins were separated by 7.5% SDS-PAGE and transferred onto nitrocellulose membranes. After being blocked with 5% milk, the membrane was treated overnight (4°C) with rabbit polyclonal phospho-Src family Tyr416 antibody (anti-pY416Src; 1:1,000), followed by 1 h at room temperature in the presence of the secondary antibody (goat anti-rabbit, 1:2,000) conjugated with horseradish peroxidase (HRP). The signal was generated using SuperSignal West Femto chemiluminescence substrate, and the light emitted from the bands was directly captured using the EpiChemi II Darkroom gel documentation system (UVP, Upland, CA). For repeated immunoblotting, membranes were stripped and reprobed with mouse monoclonal antibody against total c-Src (1:67; recognizes v-Src and c-Src) using the appropriate secondary antibody (goat anti-mouse, 1:100,000).

Reagents. Rabbit polyclonal anti-pY416Src, HRP-conjugated goat anti-rabbit IgG, and prestained protein marker were purchased from Cell Signaling Technology (Beverly, MA). Mouse anti-myosin heavy chain, mouse anti-CD34, and Texas red-conjugated goat anti-mouse IgG were from Santa Cruz Biotechnology (Santa Cruz, CA). GIBCO 0.05% trypsin-EDTA solution was from Invitrogen (Carlsbad, CA). HRP-conjugated goat anti-mouse IgG, Restore Western Stripping Buffer, and SuperSignal West Femto chemiluminescence substrate were from Pierce Biotechnology (Rockford, IL). Fura 2, fura 2-AM, and Pluronic F-127 were purchased from Molecular Probes (Eugene, OR). PP2, PP3, bisbenzimide H 33258 fluorochrome 3HCl, and mouse monoclonal anti-c-Src were from Calbiochem (San Diego, CA). All other chemicals were purchased from Sigma (St. Louis, MO). The Tyrode’s solution used in the perfused juxtamedullary nephron studies was composed of (in mM) 1.8 CaCl2·2H2O, 1 MgCl2·6H2O, 2.7 KCl, 138 NaCl, 0.35 Na2HPO4, and 5.5 D-glucose. The PSS used in preparing preglomerular microvascular explants was composed of (in mM) 145 NaCl, 4 KCl, 1.5 CaCl2, 5.5 D-glucose, and 10 HEPES, with 100 U/ml penicillin and 100 µg/ml streptomycin. For measurement of arteriolar [Ca2+]i responses, all agents were administered via the normal Ringer bath (in mM: 148 NaCl, 5 KCl, 1 MgSO4, 1.6 Na2HPO4, 0.4 NaH2PO4, 1.5 CaCl2, and 5 D-glucose).

Statistical analyses. Statistical analysis was performed by ANOVA, repeated-measures ANOVA, or Friedman’s repeated-measures ANOVA on ranks, followed by the Newman-Keuls multiple range test, as appropriate. Statistical computations were performed with the SigmaStat 3.01 software package (SPSS), with statistical significance defined as P < 0.05. All data are reported as means ± SE.


   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
Effect of Src family kinase inhibition on afferent arteriolar constrictor responses to ANG II. Afferent lumen diameter averaged 22.6 ± 1.6 µm (n = 6) under baseline conditions (Fig. 1A), and 1, 10, and 100 nM ANG II reduced afferent diameter by 3.1 ± 1.4, 7.9 ± 2.1, and 10.4 ± 1.9 µm, respectively. Removal of ANG II from the bath allowed restoration of arteriolar diameter to 22.8 ± 1.9 µm. The Src family kinase inhibitor PP2 (10 µM) did not alter baseline afferent arteriolar diameter (23.5 ± 1.7 µm; P = 0.417) but suppressed ANG II-induced vasoconstriction (2-way repeated-measures ANOVA, treatment x ANG II concentration: P = 0.017). During exposure to PP2, 1, 10, and 100 nM ANG II reduced afferent diameter by 1.4 ± 0.4, 5.6 ± 1.1, and 7.2 ± 1.9 µm (P < 0.05 vs. untreated), respectively. Inhibition of Src family protein tyrosine kinase activity attenuated the afferent arteriolar response to 100 nM ANG II by 33 ± 6%.



View larger version (21K):
[in this window]
[in a new window]
  		Fig. 1. Effect of Src family kinase inhibition on juxtamedullary afferent arteriolar contractile responses to ANG II. A: responses to ANG II before (Untreated) and during Src family kinase inhibition (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]-pyrimidine; PP2). B: responses to ANG II before (Untreated) and during treatment with the inactive compound (4-amino-7-phenylpyrazolo[3,4-d]pyrimidine; PP3). *P < 0.05 vs. baseline (0 nM ANG II). {dagger}P < 0.05 vs. untreated vs. PP2.

 
The effect of PP3 (inactive analog of PP2) on afferent arteriolar diameter responses to exogenous ANG II is depicted in Fig. 1B. Afferent arteriolar diameter averaged 20.5 ± 1.2 µm (n = 7) under baseline conditions and decreased by 3.2 ± 0.7, 6.9 ± 1.2, and 7.6 ± 1.3 µm during exposure to 1, 10, and 100 nM ANG II, respectively. During the recovery period, afferent lumen diameter returned to 20.2 ± 1.2 µm (P > 0.05 vs. untreated baseline). Subsequent exposure to 10 µM PP3 did not significantly alter baseline diameter (20.0 ± 1.5 µm) or vasoconstrictor responsiveness to ANG II (1 nM, {Delta} = –2.7 ± 0.8 µm; 10 nM, {Delta} = –5.2 ± 0.7 µm; 100 nM, {Delta} = –6.2 ± 1.2 µm).

Characterization of cultured PVSMCs. Cells cultured from preglomerular microvessel explants were characterized as vascular smooth muscle by morphological criteria (spindle-like or stellate shape) and immunostaining criteria. As shown in Fig. 2, the cultured cells utilized in the present study stained positive for {alpha}-smooth muscle actin and myosin heavy chain, with no staining evident for CD34.



View larger version (15K):
[in this window]
[in a new window]
  		Fig. 2. Representative preglomerular microvascular smooth muscle cell (PVSMC) immunostaining for {alpha}-smooth muscle actin (green; A) and myosin heavy chain (red; B). The cells stained negative for the endothelial marker CD34 (red immunostaining absent in C). Blue, nuclear staining (bisbenzamide H 33258).

 
Effect of Src family kinase inhibition on [Ca2+]i responses to 100 nM ANG II. Figure 3 illustrates the effects of PP2 and PP3 on [Ca2+]i responses to ANG II in unpassaged PVSMCs studied after 3–5 days in culture. Basal [Ca2+]i averaged 45 ± 3 nM (n = 37) and was not significantly altered by treatment with either 10 µM PP2 ({Delta} = –13 ± 5 nM, n = 13) or 10 µM PP3 ({Delta} = –3 ± 2 nM, n = 11). Although Src family tyrosine kinase inhibition failed to alter basal [Ca2+]i under these experimental conditions, responses to ANG II were significantly affected. In the untreated group (n = 13), 100 nM ANG II caused a typical rapid [Ca2+]i increase that peaked at 293 ± 66 nM above baseline (peak response) followed by a decline in [Ca2+]i until it achieved a plateau 23 ± 8 nM above baseline (P < 0.05; measured 3 min after the peak based on preliminary experiments). Compared with responses of untreated PVSMCs, both the peak and plateau phases of the [Ca2+]i response to ANG II were blunted significantly in cells treated with the Src family kinase inhibitor PP2. The magnitude of the peak response was reduced by 52% in PP2-treated cells, with no plateau phase evident ({Delta} = 3 ± 2 nM; P < 0.05 vs. untreated plateau response). The inactive compound PP3 did not significantly change the amplitude of the peak ({Delta} = 263 ± 59 nM) or the plateau ({Delta} = 16 ± 6 nM) of the [Ca2+]i response to ANG II. Thus Src family kinase inhibition attenuated the peak ANG II-induced increase in [Ca2+]i and abrogated the plateau phase of the response in renal PVSMCs.



View larger version (16K):
[in this window]
[in a new window]
  		Fig. 3. Effect of Src family kinase inhibition on intracellular free Ca2+ concentration ([Ca2+]i) responses to ANG II in unpassaged PVSMCs. A: typical responses to 100 nM ANG II are shown for untreated cells and cells pretreated with either the Src family tyrosine kinase inhibitor PP2 or its inactive analog PP3. B: summary data showing mean peak (filled bars) and plateau (hatched bars) responses to 100 nM ANG II in each treatment group. *P < 0.05 vs. untreated peak. {dagger}P < 0.05 vs. untreated plateau.

 
Effect of ANG II on c-Src phosphorylation in PVSMCs. Figure 4 illustrates the effect of ANG II on Src phosphorylation as assessed in cell lysates immunoprecipitated with anti-c-Src. ANG II did not alter c-Src protein levels at any time point within the 5-min treatment regimen. Phosphorylation of Src at Y416 was increased transiently by exposure of PVSMCs to 100 nM ANG II, averaging approximately two times baseline when measured 1 min after ANG II exposure. The Src family tyrosine kinase inhibitor PP2 prevented this phosphorylation response. The effect of ANG II to stimulate Src phosphorylation waned by the 2-min time point, with phosphorylated Src levels numerically similar to baseline evident after 5 min.



View larger version (37K):
[in this window]
[in a new window]
  		Fig. 4. c-Src phosphorylation in cultured PVSMCs exposed to ANG II in the absence (n = 4) or presence (n = 3) of PP2. After immunoprecipitation (IP) with c-Src, Western blot analysis was performed using an antibody against phospho-Tyr416 (pY416)Src. The membrane was stripped and reprobed for total c-Src. A: representative blots. B: summary of densitometric analysis.

 

   DISCUSSION
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
Accumulating evidence suggests that G protein-coupled receptors, such as the AT1R, can take advantage of signaling pathways involving receptor- and non-receptor-tyrosine kinases to exert their effects on cells. We recently reported that afferent and efferent arteriolar contractile responses to ANG II involve tyrosine kinase(s), including the EGFR tyrosine kinase (5). Moreover, EGFR tyrosine kinase activity contributes to the afferent arteriolar intracellular [Ca2+]i response to ANG II through a process that promotes Ca2+ influx (10). The present study extends these observations to implicate the Src family of non-receptor-tyrosine kinases in the afferent arteriolar contractile response to ANG II, including effects on ANG II-induced [Ca2+]i responses in PVSMCs.

The pyrazolopyrimidine PP2 was utilized to assess the role of Src activity in functional responses to ANG II. PP2 interacts with the ATP-binding site within the tyrosine kinase domain of Src, presumably preventing enzyme activation by interfering with autophosphorylation at Y416. The ability of PP2 to prevent Src phosphorylation is in accord with previous reports (35). PP2 does not discriminate between Src family members because the kinase domain is highly conserved within the family (45). The ability of PP2 to prevent Src phosphorylation is in accord with previous reports (35). PP2 inhibits Src family kinases with IC50 values in the low nanomolar range (2, 18); a few other protein kinases (Csk, p38) are inhibited an order of magnitude less potently (2). At the concentration employed in the present study (10 µM), PP2 virtually abolishes Src family kinase activity but may also reduce p38 and MAPK activities by 50–75% as indicated by in vitro kinase assays (2). Thus we cannot rule out a direct or indirect (via Src) involvement of p38 and MAPK in the effects of PP2 in the present study. However, a primary involvement of Src family members in the preglomerular microvascular effects of PP2 is highly likely, especially in light of the demonstration that this agent prevents ANG II-induced c-Src phosphorylation.

When studied using the in vitro blood-perfused juxtamedullary nephron technique, the afferent arteriole displays basal tone that includes a myogenic component (but not a tubuloglomerular feedback component due to the acute papillectomy), as well as the likely influence of myriad vasoactive substances delivered via the perfusate blood or through paracrine processes (7). The lack of an effect of PP2 on basal diameter suggests minimal involvement of Src in establishing myogenic tone and/or other tonic vasoactive influences on the afferent arteriole under our experimental conditions, in accord with our previous reports that broad-spectrum tyrosine kinase inhibition (AG9) has no effect on afferent arteriolar tone (5). However, the ability of PP2 to attenuate afferent arteriolar contractile responses to ANG II indicates involvement of Src family kinase activity in the signaling network activated by engagement of the AT1R, presumably in the resident PVSMCs.

Although studies using the in vitro blood-perfused juxtamedullary nephron technique provide useful insight into afferent arteriolar function, the vasculature studied in this setting is subject to nitric oxide-dependent regulation of basal tone and ANG II responsiveness (23). As Src is a known regulator of endothelial nitric oxide synthase (20), further investigation of Src involvement in ANG II activation of PVSMCs was pursued using cells cultured from preglomerular microvascular explants (primarily interlobular arterial and afferent arteriolar segments). These cells stained positive for {alpha}-smooth muscle actin and myosin heavy chain (using an antibody that recognizes SM1 and SM2 isoforms), with no immunostaining evident for CD34 (a glycoprotein expressed by hematopoietic progenitor cells, endothelial cells, and fibroblasts) (15). Although sometimes detected during glomerular disease, normal mesangial cells do not express SM1, SM2, {alpha}-smooth muscle actin, or CD34 (25, 27, 29, 37). Based on these characteristics, as well as morphological criteria, the cells cultured from preglomerular explants were considered authentic PVSMCs. We cannot rule out the possibility that the PVSMCs undergo transformation in culture. To minimize the likelihood of this occurrence, [Ca2+]i responses were studied in PVSMCs maintained only 3–5 days in culture; however, three to five passages were necessary to obtain sufficient PVSMCs for immunoblotting studies. Although phenotypic transformation may have occurred in PVSMCs maintained in culture for three to five passages, we note that the responses of these cells (ANG II activation of c-Src) are consistent with those obtained after 3–5 days in culture and in intact afferent arterioles studied using the in vitro blood-perfused juxtamedullary nephron technique (Src kinase inhibition blunts ANG II-induced responses).

ANG II evokes a rapid increase in vascular smooth muscle [Ca2+]i, which represents a primary determinant of contraction. However, contractile responses can also be influenced by phosphorylation-dependent changes in the Ca2+ sensitivity of the contractile apparatus. Indeed, Src family protein tyrosine kinases appear to be involved in Rho-kinase-mediated Ca2+ sensitization of coronary arterial contraction (28). ANG II-induced Ca2+ signaling events may also lead to Src activation via Pyk2 (a Ca2+-sensitive tyrosine kinase), with consequent effects on Ca2+ sensitivity. In these two scenarios, Src activity promotes the contractile response to ANG II but is not a determinant of the [Ca2+]i response. On the other hand, Src kinase activity has been implicated in tracheal smooth muscle [Ca2+]i responses to serotonin (40) and the [Ca2+]i response of human VSMCs to ANG II (43), situations in which Src activity is required for full expression of the ANG II-induced [Ca2+]i response. To distinguish between these two potential mechanisms through which Src might contribute to ANG II-induced contraction in the preglomerular microvasculature, we assessed the effects of PP2 on [Ca2+]i responses of individual fura 2-loaded PVSMCs. Neither PP2 nor PP3 altered basal [Ca2+]i, in accord with the failure of the agents to alter basal tone in perfused juxtamedullary nephrons. Moreover, Src family kinase inhibition blunted the peak and virtually abolished the plateau [Ca2+]i responses to ANG II, whereas PP3 (the inactive analog) had no effect. Thus Src family kinase activity and/or its downstream effectors ultimately influence Ca2+ influx or Ca2+ release events in the renal preglomerular microvasculature. Both Ca2+ influx and Ca2+ mobilization from intracellular stores contribute to the transient peak phase of the afferent arteriolar [Ca2+]i response to ANG II, whereas the sustained plateau phase of the [Ca2+]i response reflects only Ca2+ influx (10, 26). Thus the effect of PP2 on the PVSMC [Ca2+]i response to ANG II is suggestive of an effect on Ca2+ influx. Tyrosine kinases, including Src, have been suggested to regulate various ion channels (1, 21, 46), including the L-type Ca2+ channels that play a predominant role in ANG II-induced Ca2+ influx in the afferent arteriole. Thus it is possible that Src promotes the [Ca2+]i response to ANG II in PVSMCs via effects on voltage-gated Ca2+ influx. In contrast, Src activity contributes to the ANG II-induced contractile responses of human VSMCs isolated from resistance arteries in adipose tissue via effects on Ca2+ mobilization (43). The apparent role for Src in promoting ANG II-induced Ca2+ influx in PVSMCs, rather than the effect on Ca2+ mobilization that occurs in other VSMC populations, may reflect a species difference or the general prominence of Ca2+ influx mechanisms in the preglomerular microvasculature relative to other vascular beds.

As Src kinase inhibition did not alter basal afferent arteriolar diameter or PVSMC [Ca2+]i, tonic levels of Src activity appear insufficient to contribute to ANG II-induced responses. Thus the ability of ANG II to provoke Src kinase activation was assessed in ANG II-treated PVSMCs by Western blot analysis of Src phosphorylation. Src activity is regulated by phosphorylation at two sites: Y416, located in the activation loop of the kinase domain (phosphorylation increases enzyme activity) and Y527, located in the COOH-terminal tail (phosphorylation decreases enzyme activity). The antibody employed in these studies detects Src only when phosphorylated at Y416, thereby indicting enzyme activation. Although this antibody can react with other Src family members when phosphorylated at the corresponding sites, the use of c-Src immunoprecipitates for the phosphoanalysis makes it highly likely that our observations reflect phosphorylation of c-Src at Y416. However, other Src family members may also be activated in response to ANG II and participate in the PP2-sensitive component of the contractile response. ANG II provoked c-Src phosphorylation within the time frame (≤1 min) required for a potential contribution of this event to the contractile response. The c-Src phosphorylation response was transient, in accord with previous observations in cultured (1–4 passages) VSMCs from human small arteries (43) and rat mesenteric arteries (44).

The signaling cascade through which Src is involved in ANG II-induced [Ca2+]i and contractile responses of the preglomerular microvasculature is not known. In rat aortic VSMCs, Src plays a critical role in rapid ANG II activation of Ras (36) and ERK (12), although a contribution of these processes to contraction has not been established. The effects of Src inhibition unveiled by the present study are reminiscent of the effects of EGFR tyrosine kinase inhibition, which attenuates the juxtamedullary afferent arteriolar contractile response to ANG II and reduces the peak and plateau phases of the [Ca2+]i response of isolated afferent arterioles (5, 10). As ANG II has been shown to induce association of Src with the EGFR in rat aortic myocytes (13), it is possible that these two tyrosine kinases operate in the same branch of the ANG II-induced contractile signaling network. Src has been suggested to act upstream or downstream of the EGFR in various cell systems (11, 50); thus further studies are required to clarify the relationship between Src and the EGFR in the signaling events that contribute to ANG II-induced contractile responses in the preglomerular microvasculature.

In summary, studies using the rat in vitro blood-perfused juxtamedullary nephron technique revealed that Src family kinase inhibition attenuated afferent arteriolar contractile responses to ANG II. In rat PVSMCs maintained 3–5 days in culture, Src family kinase inhibition blunted the peak [Ca2+]i response to ANG II and abrogated the plateau phase of the response. Immunoprecipitation and immunoblotting studies confirmed the effect of ANG II to rapidly activate c-Src in cultured PVSMCs. We conclude that ANG II acts on PVSMCs to provoke rapid activation of Src family kinase(s), including c-Src, which contributes to the [Ca2+]i response and, ultimately, to vasoconstriction. These observations indicate that the physiological context within which the Src family of tyrosine kinases is viewed to influence vascular function must include not only proliferative responses but also agonist-induced contractile function in the renal microvasculature. Additional studies are required to determine whether Src is involved in afferent arteriolar contractile responses to other agonists, efferent arteriolar contractile responses, and/or vasoconstrictor responses in other microvascular beds. Further investigation in this arena may unveil mechanisms through which chronic proproliferative states (such as ANG II-dependent hypertension) could influence arteriolar tone via tyrosine kinase-mediated events.


   GRANTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
These studies were supported by funding from the National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK-39202) and a Predoctoral Fellowship from the Heartland Affiliate of the American Heart Association.


   ACKNOWLEDGMENTS
 
The authors thank Rachel W. Fallet for excellent technical support.


   FOOTNOTES
 

Address for reprint requests and other correspondence: P. K. Carmines, Dept. of Cellular and Integrative Physiology, Univ. of Nebraska College of Medicine, 985850 Nebraska Medical Ctr., Omaha, NE 68198-5850 (E-mail: pcarmines{at}unmc.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Alioua A, Mahajan A, Nishimaru K, Zarei MM, Stefani E, and Toro L. Coupling of c-Src to large conductance voltage-and Ca2+-activated K+ channels as a new mechanism of agonist-induced vasoconstriction. Proc Nat Acad Sci USA 99: 14560–14565, 2002.[Abstract/Free Full Text]
  2. Bain J, McLauchlan H, Elliott M, and Cohen P. The specificities of protein kinase inhibitors: an update. Biochem J 371: 199–204, 2003.[CrossRef][ISI][Medline]
  3. Banes A, Florian JA, and Watts SW. Mechanisms of 5-hydroxytryptamine2A receptor activation of the mitogen-activated protein kinase pathway in vascular smooth muscle. J Pharmacol Exp Ther 291: 1179–1187, 1999.[Abstract/Free Full Text]
  4. Brinson AE, Harding T, Diliberto PA, He YQ, Li X, Hunter D, Herman B, Earp HS, and Graves LM. Regulation of a calcium-dependent tyrosine kinase in vascular smooth muscle cells by angiotensin II and platelet-derived growth factor: dependence on calcium and the actin cytoskeleton. J Biol Chem 273: 1711–1718, 1998.[Abstract/Free Full Text]
  5. Carmines PK, Fallet RW, Che Q, and Fujiwara K. Tyrosine kinase involvement in renal arteriolar constrictor responses to angiotensin II. Hypertension 37: 569–573, 2001.[Abstract/Free Full Text]
  6. Carmines PK, Fowler BC, and Bell PD. Segmentally distinct effects of depolarization on intracellular [Ca2+] in renal arterioles. Am J Physiol Renal Fluid Electrolyte Physiol 265: F677–F685, 1993.[Abstract/Free Full Text]
  7. Carmines PK and Inscho EW. Perfusate composition modulates in vitro renal microvascular pressure responsiveness in a segment-specific manner. Microvasc Res 43: 347–351, 1992.[CrossRef][ISI][Medline]
  8. Carter RW and Kanagy NL. Tyrosine kinases regulate intracellular calcium during {alpha}2-adrenergic contraction in rat aorta. Am J Physiol Heart Circ Physiol 283: H1673–H1680, 2002.[Abstract/Free Full Text]
  9. Casellas D and Navar LG. In vitro perfusion of juxtamedullary nephrons in rats. Am J Physiol Renal Fluid Electrolyte Physiol 246: F349–F358, 1984.[Abstract/Free Full Text]
  10. Che Q and Carmines PK. Angiotensin II triggers EGFR tyrosine kinase-dependent Ca2+ influx in afferent arterioles. Hypertension 40: 700–706, 2002.[Abstract/Free Full Text]
  11. Daub H, Wallasch C, Lankenau A, Herrlich A, and Ullrich A. Signal characteristics of G protein-transactivated EGF receptor. EMBO J 16: 7032–7044, 1997.[CrossRef][ISI][Medline]
  12. Eguchi S, Iwasaki H, Inagami T, Numaguchi K, Yamakawa T, Motley ED, Owada KM, Marumo F, and Hirata Y. Involvement of PYK2 in angiotensin II signaling of vascular smooth muscle cells. Hypertension 33: 201–206, 1999.[Abstract/Free Full Text]
  13. Eguchi S, Numaguchi K, Iwasaki H, Matsumoto T, Yamakawa T, Utsunomiya H, Motley ED, Kawakatsu H, Owada KM, Hirata Y, Marumo F, and Inagami T. Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. J Biol Chem 273: 8890–8896, 1998.[Abstract/Free Full Text]
  14. Endlich N, Endlich K, Taesch N, and Helwig JJ. Culture of vascular smooth muscle cells from small arteries of the rat kidney. Kidney Int 57: 2468–2475, 2000.[CrossRef][ISI][Medline]
  15. Fina L, Molgaard HV, Robertson D, Bradley NJ, Monaghan P, Delia D, Sutherland DR, Baker MA, and Greaver MF. Expression of the CD34 gene in vascular endothelial cells. Blood 75: 2417–2426, 1990.[Abstract/Free Full Text]
  16. Grynkiewicz G, Poenie M, and Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 260: 3440–3450, 1985.[Abstract/Free Full Text]
  17. Hall DA, Carmines PK, and Sansom SC. Dihydropyridine-sensitive Ca2+ channels in human glomerular mesangial cells. Am J Physiol Renal Physiol 278: F97–F103, 2000.[Abstract/Free Full Text]
  18. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, Pollok BA, and Connelly PA. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor: study of Lck- and FynT-dependent T cell activation. J Biol Chem 271: 695–701, 1996.[Abstract/Free Full Text]
  19. Harris RC. EGF receptor activation by G-protein coupled receptors. Kidney Int 58: 898–899, 2000.[CrossRef][ISI][Medline]
  20. He H, Venema VJ, Gu X, Venema RC, Marrero MB, and Caldwell RB. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J Biol Chem 274: 25130–25135, 1999.[Abstract/Free Full Text]
  21. Hu XQ, Singh N, Mukhopadhyay D, and Akbarali HI. Modulation of voltage-dependent Ca2+ channels in rabbit colonic smooth muscle cells by c-Src and focal adhesion kinase. J Biol Chem 273: 5337–5342, 1998.[Abstract/Free Full Text]
  22. Ikenaga H, Fallet RW, and Carmines PK. Contribution of tubuloglomerular feedback to renal arteriolar angiotensin II responsiveness. Kidney Int 49: 34–39, 1996.[ISI][Medline]
  23. Ikenaga H, Fallet RW, and Carmines PK. Basal nitric oxide production curtails arteriolar vasoconstrictor responses to ANG II in rat kidney. Am J Physiol Renal Fluid Electrolyte Physiol 271: F365–F373, 1996.[Abstract/Free Full Text]
  24. Ishida M, Ishida T, Thomas SM, and Berk BC. Activation of extracellular signal-regulated kinases (ERK1/2) by angiotensin II is dependent on c-Src in vascular smooth muscle cells. Circ Res 82: 7–12, 1998.[Abstract/Free Full Text]
  25. Kimura K, Nagai R, Sakai T, Aikawa M, Kuro-o M, Kobayashi N, Shirato I, Inagami T, Oshi M, Suzuki N, Oba S, Mise N, Tojo A, Hirata Y, Goto A, Yazaki Y, and Omata M. Diversity and variability of smooth muscle phenotypes of renal arterioles as revealed by myosin isoform expression. Kidney Int 48: 372–382, 1995.[ISI][Medline]
  26. Loutzenhiser K and Loutzenhiser R. Angiotensin II-induced Ca2+ influx in renal afferent and efferent arterioles: differing roles of voltage-gated and store-operated Ca2+ entry. Circ Res 87: 551–557, 2000.[Abstract/Free Full Text]
  27. Makino H, Kashihara N, Sugiyama H, Kanao K, Sekikawa T, Okamoto K, Maeshima Y, Ota Z, and Nagai R. Phenotypic modulation of the mesangium reflected by contractile proteins in diabetes. Diabetes 45: 488–495, 1996.[Abstract]
  28. Nakao F, Kobayashi S, Mogami K, Mizukami Y, Shirao S, Miwa S, Todoroki-Ikeda N, Ito M, and Matsuzaki M. Involvement of Src family protein tyrosine kinases in Ca2+ sensitization of coronary artery contraction mediated by a sphingosylphosphorylcholine-Rho-kinase pathway. Circ Res 91: 953–960, 2002.[Abstract/Free Full Text]
  29. Naruse K, Fujieda M, Miyazaki E, Hayashi Y, Kuroda N, Nakayama H, Kiyoku H, Hiroi M, Kurashige T, and Enzan H. CD34 expression as a novel marker of transformed mesangial cells in biopsied glomerular diseases. J Pathol 189: 105–111, 1999.[CrossRef][ISI][Medline]
  30. Oda Y, Renaux B, Bjorge J, Saifeddine M, Fujita DJ, and Hollenberg MD. cSrc is a major cytosolic tyrosine kinase in vascular tissue. Can J Physiol Pharmacol 77: 606–617, 1999.[CrossRef][ISI][Medline]
  31. Oeckler RA, Kaminski PM, and Wolin MS. Stretch enhances contraction of bovine coronary arteries via an NAD(P)H oxidase-mediated activation of the extracellular signal-regulated kinase mitogen-activated protein kinase cascade. Circ Res 92: 23–31, 2003.[Abstract/Free Full Text]
  32. Ohishi K, Carmines PK, Inscho EW, and Navar LG. EDRF-angiotensin II interactions in rat juxtamedullary afferent and efferent arterioles. Am J Physiol Renal Fluid Electrolyte Physiol 263: F900–F906, 1992.[Abstract/Free Full Text]
  33. Poenie M. Alteration of intracellular fura-2 fluorescence by viscosity: a simple correction. Cell Calcium 11: 85–91, 1990.[CrossRef][ISI][Medline]
  34. Roberts RE. Role of the extracellular signal-regulated kinase (Erk) signal transduction cascade in {alpha}2 adrenoceptor-mediated vasoconstriction in porcine palmar lateral vein. Br J Pharmacol 133: 859–866, 2001.[CrossRef][ISI][Medline]
  35. Schenone S, Bruno O, Ranise A, Bondavalli F, Brullo C, Fossa P, Mosti L, Menozzi G, Carraro F, Naldini A, Bernini C, Manetti F, and Botta M. New pyrazolo[3,4-d]pyrimidines endowed with A431 antiproliferative activity and inhibitory properties of Src phosphorylation. Bioorg Med Chem Lett 14: 2511–2517, 2004.[CrossRef][Medline]
  36. Schieffer B, Paxton WG, Chai Q, Marrero MB, and Bernstein KE. Angiotensin II controls p21ras activity via pp60c-src. J Biol Chem 271: 10329–10333, 1996.[Abstract/Free Full Text]
  37. Stephenson LA, Haney LB, Hussaini IM, Karns LR, and Glass WF. Regulation of smooth muscle {alpha}-actin expression and hypertrophy in cultured mesangial cells. Kidney Int 54: 1175–1187, 1998.[CrossRef][ISI][Medline]
  38. Thomas SM and Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13: 513–609, 1997.[CrossRef][ISI][Medline]
  39. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA, and Smith RD. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45: 205–251, 1993.[ISI][Medline]
  40. Tolloczko B, Turkewitsch P, Choudry S, Bisotto S, Fixman ED, and Martin JG. Src modulates serotonin-induced calcium signaling by regulating phosphatidylinositol 4,5-bisphosphate. Am J Physiol Lung Cell Mol Physiol 282: L1305–L1313, 2002.[Abstract/Free Full Text]
  41. Touyz RM and Schiffrin EL. Angiotensin II regulates vascular smooth muscle cell pH, contraction, and growth via tyrosine kinase-dependent signaling pathways. Hypertension 30: 222–229, 1997.[Abstract/Free Full Text]
  42. Touyz RM and Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 52: 639–672, 2000.[Abstract/Free Full Text]
  43. Touyz RM, Wu XH, He G, Park JB, Chen X, Vacher J, Rajapurohitam V, and Schiffrin EL. Role of c-Src in the regulation of vascular contraction and Ca2+ signaling by angiotensin II in human vascular smooth muscle cells. J Hypertens 19: 441–449, 2001.[CrossRef][ISI][Medline]
  44. Touyz RM, Wu XH, He G, Salomon S, and Schiffrin EL. Increased angiotensin II-mediated Src signaling via epidermal growth factor receptor transactivation is associated with decreased C-terminal Src kinase activity in vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension 39: 479–485, 2002.[Abstract/Free Full Text]
  45. Vojtechová M, Tuhácková Z, Hlavácek J, Velek J, and Sovová V. The v-Src and c-Src tyrosine kinases immunoprecipitated from Rous sarcoma virus-transformed cells display different peptide substrate specificities. Arch Biochem Biophys 421: 277–282, 2004.[CrossRef][ISI][Medline]
  46. Wijetunge S, Lymn JS, and Hughes AD. Effects of protein tyrosine kinase inhibitors on voltage-operated calcium channel currents in vascular smooth muscle cells and pp60c-src kinase activity. Br J Pharmacol 129: 1347–1354, 2000.[CrossRef][ISI][Medline]
  47. Yang ZW, Wang J, Zheng T, Altura BT, and Altura BM. Low [Mg2+]o induces contraction of cerebral arteries: roles of tyrosine and mitogen-activated protein kinases. Am J Physiol Heart Circ Physiol 279: H152–H194, 2000.
  48. Yu H, Li X, Marchetto GS, Dy R, Hunter D, Calvo B, Dawson TL, Wilm M, Anderegg RJ, Graves LM, and Earp HS. Activation of a novel calcium-dependent protein-tyrosine kinase: correlation with c-Jun N-terminal kinase but not mitogen-activated protein kinase activation. J Biol Chem 271: 29993–29998, 1996.[Abstract/Free Full Text]
  49. Zubkov AY, Rollins S, Parent AD, and Zhang J. Mechanism of endothelin-1-induced contraction in rabbit basilar artery. Stroke 31: 526–533, 2000.[Abstract/Free Full Text]
  50. Zwick E, Hackel PO, Prenzel N, and Ullrich A. The EGF receptor as central transducer of heterologous signalling systems. Trends Pharmacol Sci 20: 408–412, 1999.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 HypertensionHome page
H. Nakashima, G. D. Frank, H. Shirai, A. Hinoki, S. Higuchi, H. Ohtsu, K. Eguchi, A. Sanjay, M. E. Reyland, P. J. Dempsey, et al.
Novel Role of Protein Kinase C-{delta} Tyr311 Phosphorylation in Vascular Smooth Muscle Cell Hypertrophy by Angiotensin II
Hypertension, February 1, 2008; 51(2): 232 - 238.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. S. Escano Jr., L. B. Keever, A. A. Gutweiler, and B. T. Andresen
Angiotensin II Activates Extracellular Signal-Regulated Kinase Independently of Receptor Tyrosine Kinases in Renal Smooth Muscle Cells: Implications for Blood Pressure Regulation
J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 34 - 42.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
288/4/F658    most recent
00392.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Che, Q.
Right arrow Articles by Carmines, P. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Che, Q.
Right arrow Articles by Carmines, P. K.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.